Joshua Richter

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

Joshua Richter, Natalia Neparidze, Lin Zhang et al. · Blood · 2012 · 166 citations · Full text

Medicine, Immunology, Oncology +16

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, David Dingli, Robert F. Cornell et al. · Journal of Clinical Oncology · 2018 · 162 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D. Cohen, Amrita Krishnan et al. · Blood · 2021 · 161 citations

Medicine, Pharmacology, Pharmacotherapy +9

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine et al. · Journal of Hematology & Oncology · 2020 · 142 citations · Full text

Medicine, Infectious Diseases, Oncology +17